Innovation

Nosyberkol is a Mycobacterium tuberculosis Small Molecule Macrophage Inhibitor

Iowa State University Research Foundation
posted on 12/10/2010

Iowa State University researchers and their collaborators have identified a compound that inhibits phagosomal maturation in macrophage cells of the mammalian immune system.

Suggested Uses

Starting point for pharmaceutical development; research tool for probing phagocytosis

Advantages

May serve as the basis for development of new antibiotics targeting edaxadiene biosynthesis


Innovation Details
 

Detailed Description

Mycobacterium tuberculosis is one of the most significant human pathogens known. It is estimated to infect nearly one third of the world’s population and causes nearly two million deaths each year. M. tuberculosis is an intracellular pathogen that is able to subvert normal phagosomal processing such that it is blocked at an early endosomal stage rather than maturing to a bactericidal phagolysosome. As part of an effort to investigate the mechanisms by which M. tuberculosis is able to prevent phagosome maturation, ISU researchers and their collaborators have identified nosyberkol (also known as isotuberculosinol and edaxadiene) as a novel M. tuberculosis diterpene virulence factor, which has been shown to arrest phagosome maturation in vitro. These researchers have also identified the enzyme that catalyzes the committed step in nosyberkol biosynthesis (halimadienyl diphosphate synthase; HPS) and identified potential HPS inhibitors. These findings have implications for new drug development as well as for probing the trafficking of intracellular pathogens and mechanisms involved in phagocytosis.

File Number: ISURF #3641 

Disease: Infectious Diseases

Other Information:

See Supporting Information


IP Protection

Copyright: None

License Online

This innovation currently is not available for online licensing. Please contact Dario Valenzuela at Iowa State University Research Foundation for more information.

Request more info via email request more info
People

Case Manager:

Dario Valenzuela Dario Valenzuela

Innovations (15)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

13,029 members 17,416 innovations 176 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...